ICE Bioscience Posters

Download

The CB1 receptor, a key component of the endocannabinoid system (ECS), is crucial in appetite control, pain perception, mood regulation, obesity, and diabetes. In oncology, the ECS plays a pivotal role in tumors' growth, development, and metastasis, with the activation or inhibition of the CB1 potentially exerting substantial impacts on cancer treatment and prevention. In vitro and in vivo modes are established to understand the signaling pathways of CB1, interactions with other cellular components and the development of more selective novel drugs with fewer side effects. CB1 receptor activation inhibits Forskolin-stimulated adenylate cyclase by G protein (Gαi/o) and increases the phosphorylation of extracellular signal-regulated kinase 1/2 (pERK1/2) via G protein-dependent and β-arrestin-dependent pathways. Here we constructed an integrated experimental cascade, including in vitro HTRF cAMP assay and β-arretin2 NanoBiT assay, to conduct the high throughput hit-to-lead compound screening, agonist, antagonist and inverse agonist validation. Meanwhile, several CDX modes are constructed for promisingly conducting in-vivo experiments and biomarker detection. Thus, ICE supports multiple approaches for helping the drug discovery and development of CB1 to facilitate the treatment of multiple diseases.